Prevalence and risk factors for microalbuminuria in a referred cohort of type II diabetic patients: A global perspective

被引:434
作者
Parving, H-H
Lewis, J. B.
Ravid, M.
Remuzzi, G.
Hunsicker, L. G.
机构
[1] Steno Diabet Ctr, DK-2820 Gentofte, Denmark
[2] Univ Aarhus, Fac Hlth Sci, DK-8000 Aarhus C, Denmark
[3] Vanderbilt Univ, Sch Med, Nashville, TN 37212 USA
[4] Tel Aviv Univ, Sackler Fac Med, IL-69978 Tel Aviv, Israel
[5] Mario Negri Inst Pharmacol Res, I-24100 Bergamo, Italy
[6] Univ Iowa, Coll Med, Dept Internal Med, Iowa City, IA 52242 USA
关键词
blood pressure; kidney function; microalbuminuria; type II diabetes;
D O I
10.1038/sj.ki.5000377
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 [临床医学]; 100201 [内科学];
摘要
We described the characteristics in a referred cohort of type 11 diabetic patients in the Developing Education on Microalbuminuria for Awareness of renal and cardiovascular risk in Diabetes study evaluating the global prevalence and determinants of microalbuminuria (MA). A cross-sectional study evaluating 32208 type 11 diabetic patients without known albuminuria from 33 countries was performed. Overall, 8057 patients were excluded, either because of prior known proteinuria or non-diabetic nephropathy (3670), or because of invalid urine collections (4387). One single random urinary albumin/creatinine ratio was obtained in 24 151 patients (75%). The overall global prevalence of normo-, micro-, and macroalbuminuria was 51, 39, and 10%, respectively. The Asian and Hispanic patients had the highest prevalence of a raised urinary albumin/creatinine ratio (55%) and Caucasians the lowest (40.6), P < 0.0001. HbA1c, systolic blood pressure,(BP), ethnicity, retinopathy, duration of diabetes, kidney function, body height, and smoking were all independent risk factors of MA, P < 0.0001. Estimated glomerular filtration rate was below 60 ml/min/1.73 m(2) in 22% of the 11573 patients with available data. Systolic BP below 130 mmHg was found in 33 and 43% had an HbA1c below 7%. The frequency of patients receiving aspirin was 32%, statins 29%, and BP-lowering therapy 63%. A high prevalence globally of MA and reduced kidney function, both conditions associated with enhanced renal and cardiovascular risk, was detected in type 11 diabetic patients without prior known nephropathy. Early detection, monitoring of vascular complications, and more aggressive multifactorial treatment aiming at renal and vascular protection are urgently needed.
引用
收藏
页码:2057 / 2063
页数:7
相关论文
共 37 条
[1]
Anavekar NS, 2004, NEW ENGL J MED, V351, P1285, DOI 10.1056/NEJMoa041365
[2]
[Anonymous], 2000, Lancet, V355, P253, DOI DOI 10.1016/S0140-6736(99)12323-7
[3]
Arauz-Pacheco Carlos, 2004, Diabetes Care, V27 Suppl 1, pS65
[4]
Baigent C, 2002, BMJ-BRIT MED J, V324, P71, DOI 10.1136/bmj.324.7329.71
[5]
Urinary albumin excretion - An independent predictor of ischemic heart disease [J].
Borch-Johnsen, K ;
Feldt-Rasmussen, B ;
Strandgaard, S ;
Schroll, M ;
Jensen, JS .
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 1999, 19 (08) :1992-1997
[6]
Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial [J].
Colhoun, HM ;
Betteridge, DJ ;
Durrington, PN ;
Hitman, GA ;
Neil, HAW ;
Livingstone, SJ ;
Thomason, MJ ;
Mackness, MI ;
Charlton-Menys, V ;
Fuller, JH .
LANCET, 2004, 364 (9435) :685-696
[7]
Collins R, 2002, LANCET, V360, P7, DOI 10.1016/S0140-6736(02)09327-3
[8]
The association of microalbuminuria and mortality in non-insulin-dependent diabetes mellitus - A systematic overview of the literature [J].
Dinneen, SF ;
Gerstein, HC .
ARCHIVES OF INTERNAL MEDICINE, 1997, 157 (13) :1413-1418
[9]
Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes [J].
Gaede, P ;
Vedel, P ;
Larsen, N ;
Jensen, GVH ;
Parving, H ;
Pedersen, O .
NEW ENGLAND JOURNAL OF MEDICINE, 2003, 348 (05) :383-393
[10]
ALBUMINURIA AND POOR GLYCEMIC CONTROL PREDICT MORTALITY IN NIDDM [J].
GALL, MA ;
BORCHJOHNSEN, K ;
HOUGAARD, P ;
NIELSEN, FS ;
PARVING, HH .
DIABETES, 1995, 44 (11) :1303-1309